Home » Stocks » VRTX

Vertex Pharmaceuticals, Inc. (VRTX)

Stock Price: $213.55 USD -1.46 (-0.68%)
Updated May 10, 2021 2:17 PM EDT - Market open
Market Cap 55.66B
Revenue (ttm) 6.41B
Net Income (ttm) 2.76B
Shares Out 259.37M
EPS (ttm) 10.49
PE Ratio 20.36
Forward PE 18.87
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $213.55
Previous Close $215.01
Change ($) -1.46
Change (%) -0.68%
Day's Open 215.63
Day's Range 213.54 - 216.28
Day's Volume 501,808
52-Week Range 202.57 - 306.08

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

If the growth stock sell-off accelerates, this Fool will be looking to open a position in each of these innovative companies.

Other stocks mentioned: CRWD, ETSY, PLTR, ZM
8 hours ago - The Motley Fool

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $215.01, marking a +0.87% move from the previous day.

2 days ago - Zacks Investment Research

The cystic fibrosis specialist is moving into other lucrative areas.

6 days ago - The Motley Fool

These two stocks are attractive buy-and-hold picks for long-term investors.

Other stocks mentioned: OKTA
1 week ago - The Motley Fool

Vertex (VRTX) beats both earnings and sales estimates in Q1 and keeps product sales outlook for 2021.

1 week ago - Zacks Investment Research

Make every dollar count.

Other stocks mentioned: UPWK
1 week ago - The Motley Fool

The biotech's improving fortunes relied on one drug.

1 week ago - The Motley Fool

Don't count these ARK Invest ETF holdings out.

Other stocks mentioned: TDOC, U
1 week ago - The Motley Fool

Vertex (VRTX) delivered earnings and revenue surprises of 7.58% and 3.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 16.41% over the past year to $2.98, which bea...

1 week ago - Benzinga

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2021 and reiterated full-year 2021 guidanc...

1 week ago - Business Wire

After a stellar rally in 2020, biotech stocks have been selling off over the past couple of months. This offers investors a buying opportunity to scoop up quality biotech stocks at cheaper prices.

Other stocks mentioned: GILD
1 week ago - InvestorPlace

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval of the label extension for KAFTRIO® (ivacaftor/tezacaftor/el...

1 week ago - Business Wire

On Vertex's (VRTX) first-quarter earnings call, investor focus is likely to be on the sales performance of its triple combo CF drug Trikafta and the company's pipeline progress.

2 weeks ago - Zacks Investment Research

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will advance the selective NaV1.8 inhibitor, VX-548, into Phase 2 clinical development with clinical t...

2 weeks ago - Business Wire

They're generating revenue now -- and more is on the way.

Other stocks mentioned: BMY, EXEL
2 weeks ago - The Motley Fool

See if the formerly high-flying biotech deserves a place in your portfolio.

2 weeks ago - The Motley Fool

Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Privately-held Obsidian Therapeutics have entered into a research collaboration and licensing agreement to discover novel therapies that regulate g...

2 weeks ago - Benzinga

BOSTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex and Obsidian Therapeutics announced a strategic research collaboration and licensing agreement for novel therapies to regulate gene editing.

2 weeks ago - Business Wire

Vertex (VRTX) to lead CRISPR Therapeutics for manufacture and commercialization of gene-editing therapy CTX001 which is being developed for treating SCD and TDT.

2 weeks ago - Zacks Investment Research

Well-known guidance from Warren Buffett can help us identify opportunities in an expensive market.

Other stocks mentioned: ALGN, RMD
2 weeks ago - The Motley Fool

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $220.16, marking a +0.45% move from the previous day.

2 weeks ago - Zacks Investment Research

Investors may want to pay close attention to news coming down the pike soon that could affect the share prices of several pharma companies. The next two months are likely to see a wave of important upda...

Other stocks mentioned: AZN, BIIB, JNJ, MRNA, PFE, SRPT
2 weeks ago - GuruFocus

The amended collaboration agreement comes with a big up-front payment.

2 weeks ago - The Motley Fool

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first-quarter 2021 financial results on Thursday, April 29, 2021 after the financial markets close. The compan...

3 weeks ago - Business Wire

Bargains abound if you're shopping for high-quality growth stocks.

Other stocks mentioned: FSLY, TRUP
3 weeks ago - The Motley Fool

They're among the top 10 holdings in one of Ark Invest's biggest funds.

Other stocks mentioned: TDOC, REGN
3 weeks ago - The Motley Fool

And they all have one key thing in common.

Other stocks mentioned: REGN, TDOC, TWST
3 weeks ago - The Motley Fool

We believe that the stock price of Vertex Pharmaceuticals is undervalued at current levels of $215. VRTX stock is up a mere 6% off the March 2020 bottom compared to the S&P which moved 85%.

3 weeks ago - Forbes

These companies are big-time bargains in the eyes of professional investors.

Other stocks mentioned: GOLD, MRK, SSRM, VTRS
3 weeks ago - The Motley Fool

Gilead Sciences, Biogen and Vertex Pharmaceuticals could top expectations in an otherwise soft quarter for biotech stocks, an analyst said Thursday. He sees key products beating forecasts.

Other stocks mentioned: BIIB, GILD, SAGE
1 month ago - Investors Business Daily

Horizon Therapeutics has a clear path to significant sales growth.

Other stocks mentioned: ABBV, BMY, HZNP, PFE, SGEN
1 month ago - The Motley Fool

Value stocks are historically the place to be when the U.S. economy is rebounding from a recession.

Other stocks mentioned: KGC, NLY
1 month ago - The Motley Fool

All three should have solid long-term growth prospects.

Other stocks mentioned: NVAX, REGN
1 month ago - The Motley Fool

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a pos...

1 month ago - Business Wire

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Australian Therapeutic Goods Administration (TGA) has approved the use of TRIKAFTA® (elexacaftor/teza...

1 month ago - Business Wire

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $211.54, moving -0.96% from the previous trading session.

1 month ago - Zacks Investment Research

They're leaders in their niche markets. And they have great growth prospects.

Other stocks mentioned: SQ, TDOC
1 month ago - The Motley Fool

Once the market's dust settles, these two successful companies will continue winning.

Other stocks mentioned: FB
1 month ago - The Motley Fool

They're pioneers in their niche markets. And they still have huge growth prospects.

Other stocks mentioned: ISRG, TDOC
1 month ago - The Motley Fool

The price is right for these stocks, which are promising big revenue.

Other stocks mentioned: NVAX, SGEN
1 month ago - The Motley Fool

These innovative stocks have the potential to skyrocket under the new administration.

Other stocks mentioned: ETSY, LOVE, OKTA, TRUP
1 month ago - The Motley Fool

Vertex Pharmaceuticals (VRTX) closed at $215.15 in the latest trading session, marking a +0.4% move from the prior day.

1 month ago - Zacks Investment Research

Vertex (VRTX) begins early-stage clinical study on cellular therapy, VX-880 for type-I diabetes. FDA also grants Fast Track status to the candidate.

1 month ago - Zacks Investment Research

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for VX-880 and that the co...

2 months ago - Business Wire

The biotech industry seems poised for further growth due to factors like advancements in drug research and faster regulatory process, making it wise to look at names like AbbVie (ABBV) and Novavax (NVAX)

Other stocks mentioned: ABBV, BMY, NVAX, REGN
2 months ago - Zacks Investment Research

These high-growth stocks should handily outperform the most-popular Reddit rally companies.

Other stocks mentioned: CRM, JUSHF
2 months ago - The Motley Fool

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?

2 months ago - Zacks Investment Research

These fast-paced businesses can supercharge investors' portfolios.

Other stocks mentioned: CRM, ZM
2 months ago - The Motley Fool

About VRTX

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitr... [Read more...]

Industry
Biotechnology
IPO Date
Jul 24, 1991
Stock Exchange
NASDAQ
Ticker Symbol
VRTX
Full Company Profile

Financial Performance

In 2020, VRTX's revenue was $6.21 billion, an increase of 49.07% compared to the previous year's $4.16 billion. Earnings were $2.71 billion, an increase of 130.42%.

Financial Statements

Analyst Forecasts

According to 28 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price forecast is 284.68, which is an increase of 33.31% from the latest price.

Price Target
$284.68
(33.31% upside)
Analyst Consensus: Buy